Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More effective diagnosis and treatments are needed to reduce the morbidity and mortality affecting malaria patients. Researchers at the Malaria Laboratory at MORU study the pathophysiology of the disease, and test new compound drugs for anti-malarial activity. In the context of growing artemisinin resistance, this research will have a global impact.

Kesinee Chotivanich: Malaria is one of the neglected diseases, and it's a disease of poor people. If you would like to reduce the morbidity or mortality of patients you need to treat them effectively, with effective diagnosis and treatment.

One of the key factors to eliminate malaria is to kill the parasites. To do that, you have to know where they are. Even in low levels or in asymptomatic cases you have to know where the parasites are in order to kill them. To prevent the transmission from people to people, we need to stop the transmission between the mosquito (the vector) and people.

So all this you need to know. Which drug will be very effective in all steps of malaria transmission. We are interested in the pathophysiology of malaria, in the factors that affect the severity of the disease. We try to see how we can protect, or help to decrease the chance to get severe malaria. Also the anti-malaria drug activity: we first screen and try to see any anti-malarial activities of new compounds, by screening to see if they help treat anti-malaria drug resistance. Because in this region (Thailand) we have a problem with multi drug resistance. That means we need new anti-malarial drugs or new treatment regimens urgently.

Q: Why does your line of research matter and why should we fund it?

KC: The hot topic is artemisinin resistance. Our group is the first to develop a new methodology to detect artemisinin-resistant parasites. We have a chance to look at new anti-malarial drugs to see if they can be used in the context of anti-malarial drug resistance in the future. To help them, to improve patient's care and to eliminate malaria, we need support. And the support should go to the people who have high capability to make high quality research and impact health policy. All the funding that goes to our group will help not only the people who have a malaria infection but will also help people everywhere.

Kesinee Chotivanich

Dr Kesinee Chotivanich heads the Malaria laboratory at MORU. This laboratory provides facilities and resources to researchers, students, and collaborators who are interested in tropical diseases, with the aim to improve patients' care. Areas of interest include the pathophysiology of malaria, host-parasite interaction, pharmacodynamics of antimalarial drugs, mechanism of antimalarial drug resistance, and development of diagnostic tools.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.